A novel method for boronating antibodies without loss of immunoreactivity, for use in neutron capture therapy

Ferro, V. A. and Morris, J. H. and Stimson, W H (1995) A novel method for boronating antibodies without loss of immunoreactivity, for use in neutron capture therapy. Drug Design and Discovery, 13 (1). pp. 13-25. ISSN 1055-9612

Full text not available in this repository.Request a copy

Abstract

The search for suitable boron containing compounds for 10B neutron capture therapy (BNCT) is based on the principle that boron atoms must be delivered specifically to tumour cells at a concentration high enough to be effective without being toxic to normal cells. Specificity may be achieved through monoclonal antibodies. However, it has been difficult to conjugate large numbers of boron atoms to the antibody molecules without inactivating them. We have devised a strategy to do this indirectly through the use of a boronated glutamate-lysine polymer in conjunction with biotin and streptavidin.

ORCID iDs

Ferro, V. A. ORCID logoORCID: https://orcid.org/0000-0003-1967-3603, Morris, J. H. and Stimson, W H;
CORE (COnnecting REpositories)